We are live on ! Find out more
ACHN

Achillion Pharmaceuticals
ACHN

Delisted

ACHN was delisted on the 27th of January, 2020.

147 hedge funds and large institutions have $852M invested in Achillion Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 55 increasing their positions, 44 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

178% more call options, than puts

Call options by funds: $10M | Put options by funds: $3.6M

25% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 44

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

1% less capital invested

Capital invested by funds: $858M → $852M (-$5.15M)

4% less funds holding

Funds holding: 153147 (-6)

15% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 20

Holders
147
Holders Change
-6
Holders Change %
-3.92%
% of All Funds
3.92%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.08%
New
17
Increased
55
Reduced
44
Closed
20
Calls
$10M
Puts
$3.6M
Net Calls
+$6.4M
Net Calls Change
-$4.11M
Name Holding Trade Value Shares
Change
Change in
Stake
TA
51
Teachers Advisors
New York
$1.46M +$120K +13,952 +8%
BA
52
BlackRock Advisors
Delaware
$1.43M +$681K +79,439 +76%
California Public Employees Retirement System
53
California Public Employees Retirement System
California
$1.42M -$48.9K -5,700 -3%
EA
54
Emerald Acquisition
Washington
$1.39M +$1.53M +178,504 New
Wells Fargo
55
Wells Fargo
California
$1.28M -$170K -19,781 -11%
CS
56
Candriam SCA
Luxembourg
$1.15M -$1.18M -137,000 -48%
TD Asset Management
57
TD Asset Management
Ontario, Canada
$1.13M +$12.9K +1,508 +1%
Creative Planning
58
Creative Planning
Kansas
$1.04M +$8.58K +1,000 +0.8%
HI
59
HBK Investments
Texas
$999K +$593K +69,100 +117%
New York State Common Retirement Fund
60
New York State Common Retirement Fund
New York
$996K
Dimensional Fund Advisors
61
Dimensional Fund Advisors
Texas
$976K -$41.2K -4,800 -4%
RhumbLine Advisers
62
RhumbLine Advisers
Massachusetts
$967K +$35.7K +4,158 +3%
Morgan Stanley
63
Morgan Stanley
New York
$911K +$669K +77,980 +201%
ProShare Advisors
64
ProShare Advisors
Maryland
$905K +$4.5K +524 +0.5%
CCI
65
Columbus Circle Investors
$859K +$298K +34,720 +46%
DAM
66
Doheny Asset Management
California
$826K -$49.8K -5,800 -5%
RJA
67
Raymond James & Associates
Florida
$813K +$44.4K +5,181 +5%
Citadel Advisors
68
Citadel Advisors
Florida
$769K -$2.11M -245,462 -71%
QIM
69
Quantitative Investment Management
Virginia
$763K +$840K +97,900 New
GC
70
Globeflex Capital
California
$680K
SCA
71
Secor Capital Advisors
New York
$680K +$545K +63,579 +270%
MLICM
72
Metropolitan Life Insurance Company (MetLife)
New York
$649K
ZIM
73
Zacks Investment Management
Illinois
$645K -$37.6K -4,383 -5%
Manulife (Manufacturers Life Insurance)
74
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$627K +$20.5K +2,391 +3%
NFA
75
Nationwide Fund Advisors
Ohio
$602K +$13.8K +1,606 +2%

ACHN Hedge Fund Activity: Q2 2016 in Review

147 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q2 2016, worth a combined $852M — down 0.6% from $858M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of ACHN and 17 opened new positions — a net loss of 3 holders — while 44 trimmed existing stakes and 55 added.

The largest buyer was Goldman Sachs, adding an estimated $11.9M. The largest seller was Janus Henderson Investors US, cutting an estimated $9.15M.

  • 147 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q2 2016, down from 153 in Q1 2016.
  • Funds reported $852M of Achillion Pharmaceuticals stock for Q2 2016, down 0.6% quarter-over-quarter.
  • 17 funds opened new Achillion Pharmaceuticals positions in Q2 2016 and 20 closed out, a net change of -3 holders.
  • The largest Achillion Pharmaceuticals buyer in Q2 2016 was Goldman Sachs, an estimated $11.9M added.
  • The largest Achillion Pharmaceuticals seller in Q2 2016 was Janus Henderson Investors US, an estimated $9.15M sold.

Based on aggregated 13F filings for Q2 2016.